What is the price target for LBRX stock?
10 analysts have analysed LBRX and the average price target is 43.35 USD. This implies a price increase of 83.07% is expected in the next year compared to the current price of 23.68.
LB PHARMACEUTICALS INC (LBRX) Forecast, Price Target & Analyst Ratings
NASDAQ:LBRX • US50180M1080
Current stock price
23.68 USD
-0.16 (-0.67%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for LB PHARMACEUTICALS INC (LBRX).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- N/A
- Period
- Q4 / 2025
- EPS Estimate
- -$0.46
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$43.35
Upside
+ 83.07%
From current price of $23.68 to mean target of $43.35, Based on 10 analyst forecasts
Low
$27.27
Median
$33.15
High
$81.90
Price Target Revisions
1 Month
0.00%
3 Months
-8.27%
Price Target Summary
10 Wall Street analysts provided a forecast for the next 12 months for LBRX. The average price target is 43.35 USD. This implies a price increase of 83.07% is expected in the next year compared to the current price of 23.68.
The average price target has been revised downward by 8.27% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
86.00%
LBRX was analyzed by 10 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about LBRX.
In the previous month the buy percentage consensus was at a similar level.
LBRX was analyzed by 10 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-27 | Stifel | Maintains | Buy -> Buy |
| 2025-12-11 | Stifel | Maintains | Buy -> Buy |
| 2025-10-06 | Leerink Partners | Initiate | Outperform |
| 2025-10-06 | Stifel | Initiate | Buy |
| 2025-10-06 | Piper Sandler | Initiate | Overweight |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- N/A
- Period
- Q4 / 2025
- EPS Estimate
- -$0.46
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- N/A
- Number of Analysts
- 6
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
3.42%
Next Earnings Summary
Full Analyst Estimates 2025 - 2027
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | |||
| EBITDA YoY % growth | -11.372M | -64.739M -469.28% | N/A | N/A | N/A | |
| EBIT YoY % growth | -11.376M | -64.83M -469.88% | N/A 55.75% | N/A -292.22% | N/A -32.55% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A -11.68% | N/A -0.43% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.46 | -0.71 | -0.90 69.34% | -1.11 -81.43% | -1.26 -177.09% |
| Revenue Q2Q % growth | |||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -11.791M -112.88% | -18.322M | -24.09M -113.41% | -30.812M -487.34% | -36.876M -212.73% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-13.96%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
LB PHARMACEUTICALS INC / LBRX Forecast FAQ
Can you provide the consensus estimates for LB PHARMACEUTICALS INC next earnings?
The consensus EPS estimate for the next earnings of LB PHARMACEUTICALS INC (LBRX) is -0.46 USD and the consensus revenue estimate is 0 USD.